San Bruno, CA, United States
San Bruno, CA, United States
SEARCH FILTERS
Time filter
Source Type

WALTHAM, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (“AMAG”) (Nasdaq:AMAG) today announced the pricing of $300 million aggregate principal amount of 3.25% Convertible Senior Notes due 2022 (the "notes") in an underwritten public offering (the "offering") registered under the Securities Act of 1933, as amended. AMAG has increased the size of the offering from the originally announced $250 million (or $287.5 million assuming full exercise of the underwriters’ over-allotment option).  J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as book-running managers and Leerink Partners LLC is acting as co-manager for the offering. Perella Weinberg Partners LP and J. Wood Capital Advisors LLC are acting as AMAG’s financial advisors for the offering.  AMAG has granted the underwriters the option to purchase, exercisable within a 30-day period, up to an additional $45 million principal amount of notes solely to cover over-allotments, if any. The offering is expected to close on May 10, 2017, subject to customary closing conditions. Interest on the notes will be paid semiannually in arrears on June 1 and December 1 of each year at the rate of 3.25% per year, beginning on December 1, 2017. The notes will mature on June 1, 2022, unless earlier repurchased or converted in accordance with their terms prior to such date. AMAG will not have the right to redeem the notes prior to maturity. Prior to March 1, 2022, the notes will be convertible at the option of holders of the notes only upon satisfaction of certain conditions and during certain periods, and thereafter, will be convertible at any time until the close of business on the business day immediately preceding the maturity date. Upon conversion, holders of the notes will receive shares of AMAG common stock, cash or a combination thereof, at AMAG's election. The conversion rate for the notes will initially be 36.5464 shares of AMAG common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $27.36 per share, and is subject to adjustment under the terms of the notes. This represents a premium of approximately 37.5% over the last reported sale price of $19.90 per share of AMAG common stock on The NASDAQ Global Select Market on May 4, 2017. Holders of the notes may require AMAG to repurchase their notes upon the occurrence of a fundamental change prior to maturity for cash at a repurchase price equal to 100% of the principal amount of the notes to be repurchased plus accrued and unpaid interest, if any. AMAG estimates that the net proceeds from the offering of the notes will be approximately $291.0 million (or approximately $334.8 million if the underwriters exercise their over-allotment option in full), after deducting the underwriters’ discount and estimated offering expenses payable by AMAG. AMAG intends to use the net proceeds from the offering of the notes together with cash on hand to repay the approximately $320.8 million of borrowings under, and terminate, its existing credit facility contemporaneously with, or shortly after, the closing of the offering. Contemporaneously with the offering of the notes, AMAG entered into privately negotiated transactions with certain investors to repurchase on or about May 10, 2017 approximately $158.9 million aggregate principal amount of its existing 2.50% Convertible Senior Notes due 2019 (the “2019 Notes”) for an aggregate repurchase price of approximately $171.3 million, including accrued interest, with cash on hand. Such repurchases of AMAG’s existing 2019 Notes could affect the market price of AMAG common stock. AMAG also expects that holders of existing 2019 Notes that sell their existing 2019 Notes to AMAG may purchase shares of AMAG common stock in the market to unwind hedge positions they have with respect to their exposure to the existing 2019 Notes in connection with such repurchase. In connection with the existing 2019 Notes, AMAG entered into convertible note hedge transactions along with warrant transactions with certain financial institutions (the “existing option counterparties”). Together with the intended repurchases of the existing 2019 Notes, AMAG entered into agreements with the existing option counterparties to terminate a portion of such existing convertible note hedge transactions in a notional amount corresponding to the amount of such existing 2019 Notes repurchased. In addition, AMAG also entered into agreements with the existing option counterparties to terminate a portion of the existing warrant transactions. In connection with any termination of existing convertible note hedge and warrant transactions and the expected unwinding of the existing hedge position of the existing option counterparties with respect to such transactions, such existing option counterparties and/or their respective affiliates may sell shares of AMAG common stock in secondary market transactions, and/or unwind various derivative transactions with respect to AMAG common stock. This activity could decrease (or reduce the size of any increase in) the market price of AMAG common stock at that time and it could decrease (or reduce the size of any increase in) the market value of the notes. The offering is being made pursuant to AMAG's shelf registration statement (including a prospectus), which was previously filed with the Securities and Exchange Commission ("SEC") and became effective on February 24, 2015, and a preliminary prospectus supplement related to the notes, filed with the SEC on May 3, 2017, and related free writing prospectuses. AMAG intends to file a final prospectus supplement setting forth the terms of the notes with the SEC. Investors should read the prospectus and the preliminary prospectus supplement including the documents incorporated by reference therein, and any free writing prospectus related to the offering for more complete information about AMAG and the offering. These documents may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies may be obtained from J.P. Morgan Securities LLC (c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by calling 1-866-803-9204) or from Morgan Stanley & Co. LLC (Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by calling (866) 718-1649 or by emailing prospectus@morganstanley.com). This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any offer or sale of, the notes or the shares of AMAG common stock issuable upon conversion of the notes, if any, in any state or jurisdiction in which the offer, solicitation, or sale of the notes would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction. Any offers, solicitations of offers to buy, or sales of the notes will only be made pursuant to the registration statement filed with and declared effective by the SEC, including a prospectus and a related preliminary prospectus supplement. AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to statements regarding: the anticipated use of proceeds of the offering and the timing of completion of the offering and repurchases of 2019 notes, are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, (1) changes in the price of AMAG common stock, (2) changes in the convertible note and other capital markets and (3) other risks identified in our Securities and Exchange Commission (SEC) filings, including AMAG's Annual Report on Form 10-K for the year ended December 31, 2016 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 and subsequent filings with the SEC. AMAG cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. AMAG Pharmaceuticals® and Feraheme® are registered trademarks of AMAG Pharmaceuticals, Inc. MuGard® is a registered trademark of Abeona Therapeutics, Inc. Makena® is a registered trademark of AMAG Pharmaceuticals IP, Ltd. Cord Blood Registry® and CBR® are registered trademarks of CBR Systems, Inc. IntrarosaTM is a trademark of Endoceutics, Inc.


News Article | November 19, 2016
Site: marketersmedia.com

Wiseguyreports.Com Adds “Stem Cell Banking -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database This report studies sales (consumption) of Stem Cell Banking in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Stem Cell Banking in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Stem Cell Banking in each application, can be divided into Application 1 Application 2 Application 3 Global Stem Cell Banking Sales Market Report 2016 1 Stem Cell Banking Overview 1.1 Product Overview and Scope of Stem Cell Banking 1.2 Classification of Stem Cell Banking 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Stem Cell Banking 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 Stem Cell Banking Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Stem Cell Banking (2011-2021) 1.5.1 Global Stem Cell Banking Sales and Growth Rate (2011-2021) 1.5.2 Global Stem Cell Banking Revenue and Growth Rate (2011-2021) 7 Global Stem Cell Banking Manufacturers Analysis 7.1 StemCyte (U.S.) 7.1.1 Company Basic Information, Manufacturing Base and Competitors 7.1.2 Stem Cell Banking Product Type, Application and Specification 7.1.2.1 Type I 7.1.2.2 Type II 7.1.3 StemCyte (U.S.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.1.4 Main Business/Business Overview 7.2 Cryo-Cell International (U.S.) 7.2.1 Company Basic Information, Manufacturing Base and Competitors 7.2.2 116 Product Type, Application and Specification 7.2.2.1 Type I 7.2.2.2 Type II 7.2.3 Cryo-Cell International (U.S.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.2.4 Main Business/Business Overview 7.3 ViaCord (U.S.) 7.3.1 Company Basic Information, Manufacturing Base and Competitors 7.3.2 133 Product Type, Application and Specification 7.3.2.1 Type I 7.3.2.2 Type II 7.3.3 ViaCord (U.S.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.3.4 Main Business/Business Overview 7.4 Cord Blood Registry (U.S.) 7.4.1 Company Basic Information, Manufacturing Base and Competitors 7.4.2 Nov Product Type, Application and Specification 7.4.2.1 Type I 7.4.2.2 Type II 7.4.3 Cord Blood Registry (U.S.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.4.4 Main Business/Business Overview 7.5 Smart Cells (U.K.) 7.5.1 Company Basic Information, Manufacturing Base and Competitors 7.5.2 Product Type, Application and Specification 7.5.2.1 Type I 7.5.2.2 Type II 7.5.3 Smart Cells (U.K.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.5.4 Main Business/Business Overview 7.6 Cryo-Save (Netherlands) 7.6.1 Company Basic Information, Manufacturing Base and Competitors 7.6.2 Million USD Product Type, Application and Specification 7.6.2.1 Type I 7.6.2.2 Type II 7.6.3 Cryo-Save (Netherlands) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.6.4 Main Business/Business Overview 7.7 Cryoviva (India) 7.7.1 Company Basic Information, Manufacturing Base and Competitors 7.7.2 Pharmaceuticals Product Type, Application and Specification 7.7.2.1 Type I 7.7.2.2 Type II 7.7.3 Cryoviva (India) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.7.4 Main Business/Business Overview 7.8 LifeCell (India) 7.8.1 Company Basic Information, Manufacturing Base and Competitors 7.8.2 Product Type, Application and Specification 7.8.2.1 Type I 7.8.2.2 Type II 7.8.3 LifeCell (India) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.8.4 Main Business/Business Overview 7.9 Cordlife (Singapore) 7.9.1 Company Basic Information, Manufacturing Base and Competitors 7.9.2 Product Type, Application and Specification 7.9.2.1 Type I 7.9.2.2 Type II 7.9.3 Cordlife (Singapore) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.9.4 Main Business/Business Overview 7.10 Cordvida (Brazil) 7.10.1 Company Basic Information, Manufacturing Base and Competitors 7.10.2 Product Type, Application and Specification 7.10.2.1 Type I 7.10.2.2 Type II 7.10.3 Cordvida (Brazil) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.10.4 Main Business/Business Overview 7.11 Cord Blood Corporation (China) For more information, please visit https://www.wiseguyreports.com/sample-request/749197-global-stem-cell-banking-sales-market-report-2016


Wiseguyreports.Com Adds “Stem Cell Banking -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database This report studies sales (consumption) of Stem Cell Banking in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering StemCyte (U.S.) Cryo-Cell International (U.S.) ViaCord (U.S.) Cord Blood Registry (U.S.) Smart Cells (U.K.) Cryo-Save (Netherlands) Cryoviva (India) LifeCell (India) Cordlife (Singapore) Cordvida (Brazil) Cord Blood Corporation (China) Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Stem Cell Banking in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Stem Cell Banking in each application, can be divided into Application 1 Application 2 Application 3 Global Stem Cell Banking Sales Market Report 2016 1 Stem Cell Banking Overview 1.1 Product Overview and Scope of Stem Cell Banking 1.2 Classification of Stem Cell Banking 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Stem Cell Banking 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 Stem Cell Banking Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Stem Cell Banking (2011-2021) 1.5.1 Global Stem Cell Banking Sales and Growth Rate (2011-2021) 1.5.2 Global Stem Cell Banking Revenue and Growth Rate (2011-2021) 7 Global Stem Cell Banking Manufacturers Analysis 7.1 StemCyte (U.S.) 7.1.1 Company Basic Information, Manufacturing Base and Competitors 7.1.2 Stem Cell Banking Product Type, Application and Specification 7.1.2.1 Type I 7.1.2.2 Type II 7.1.3 StemCyte (U.S.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.1.4 Main Business/Business Overview 7.2 Cryo-Cell International (U.S.) 7.2.1 Company Basic Information, Manufacturing Base and Competitors 7.2.2 116 Product Type, Application and Specification 7.2.2.1 Type I 7.2.2.2 Type II 7.2.3 Cryo-Cell International (U.S.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.2.4 Main Business/Business Overview 7.3 ViaCord (U.S.) 7.3.1 Company Basic Information, Manufacturing Base and Competitors 7.3.2 133 Product Type, Application and Specification 7.3.2.1 Type I 7.3.2.2 Type II 7.3.3 ViaCord (U.S.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.3.4 Main Business/Business Overview 7.4 Cord Blood Registry (U.S.) 7.4.1 Company Basic Information, Manufacturing Base and Competitors 7.4.2 Nov Product Type, Application and Specification 7.4.2.1 Type I 7.4.2.2 Type II 7.4.3 Cord Blood Registry (U.S.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.4.4 Main Business/Business Overview 7.5 Smart Cells (U.K.) 7.5.1 Company Basic Information, Manufacturing Base and Competitors 7.5.2 Product Type, Application and Specification 7.5.2.1 Type I 7.5.2.2 Type II 7.5.3 Smart Cells (U.K.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.5.4 Main Business/Business Overview 7.6 Cryo-Save (Netherlands) 7.6.1 Company Basic Information, Manufacturing Base and Competitors 7.6.2 Million USD Product Type, Application and Specification 7.6.2.1 Type I 7.6.2.2 Type II 7.6.3 Cryo-Save (Netherlands) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.6.4 Main Business/Business Overview 7.7 Cryoviva (India) 7.7.1 Company Basic Information, Manufacturing Base and Competitors 7.7.2 Pharmaceuticals Product Type, Application and Specification 7.7.2.1 Type I 7.7.2.2 Type II 7.7.3 Cryoviva (India) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.7.4 Main Business/Business Overview 7.8 LifeCell (India) 7.8.1 Company Basic Information, Manufacturing Base and Competitors 7.8.2 Product Type, Application and Specification 7.8.2.1 Type I 7.8.2.2 Type II 7.8.3 LifeCell (India) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.8.4 Main Business/Business Overview 7.9 Cordlife (Singapore) 7.9.1 Company Basic Information, Manufacturing Base and Competitors 7.9.2 Product Type, Application and Specification 7.9.2.1 Type I 7.9.2.2 Type II 7.9.3 Cordlife (Singapore) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.9.4 Main Business/Business Overview 7.10 Cordvida (Brazil) 7.10.1 Company Basic Information, Manufacturing Base and Competitors 7.10.2 Product Type, Application and Specification 7.10.2.1 Type I 7.10.2.2 Type II 7.10.3 Cordvida (Brazil) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.10.4 Main Business/Business Overview 7.11 Cord Blood Corporation (China)


News Article | December 21, 2016
Site: globenewswire.com

WALTHAM, Mass., Dec. 21, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Brian Kelley, former president and chief executive officer of Keurig Green Mountain, Inc. has been elected to AMAG’s board of directors, effective December 20, 2016. Mr. Kelley brings to the AMAG board extensive experience in the consumer products industry, along with a strong combination of operational expertise in product development and building high-profile brands.  At Keurig, he led the company through a period of significant growth, successfully rebuilding the company’s core business and completing the company’s sale in 2015. “Brian will add significant value as an AMAG board member, drawing on his more than 30 years of executive leadership experience with premier consumer product companies,” said Gino Santini, chairman of AMAG’s board of directors. “His appointment reflects our commitment to ensuring that we have a broad mix of skills and perspectives on AMAG’s board. We look forward to benefiting from his expertise as we continue to grow the company and seek additional products to expand the portfolio and leverage the consumer capabilities acquired through our acquisition of Cord Blood Registry last year.” Prior to his role at Keurig, Mr. Kelley served as president of Coca-Cola Refreshments, the company’s North American operating business unit. He also served as the president and chief executive officer of SIRVA, Inc., a Clayton, Dubilier & Rice portfolio company. Under his leadership, SIRVA went public in 2003. “I am excited to be joining AMAG’s board at a time of significant organic growth and expansion through business development,” said Mr. Kelley. “AMAG has an interesting mix of products in both the women’s health and hematology/oncology space, as well as unique consumer engagement and digital marketing capabilities.  I am looking forward to working with management and the board to build upon these platforms to maximize their product growth opportunities.” Mr. Kelley began his career at Procter & Gamble holding various sales and brand management positions, followed by roles of increasing responsibility at Ford Motor Company and General Electric Company. He received a bachelor’s degree in economics from the College of the Holy Cross. About AMAG AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws.  Any statements contained herein which do not describe historical facts, including, among others, statements regarding AMAG’s intention to grow the company and seek additional products to expand its’ portfolio and leverage its’ consumer capabilities, Mr. Kelley’s expected contributions to AMAG’s board, AMAG’s ability to execute its growth strategy and build upon its existing platforms and maximize product growth opportunities, and beliefs that newborn stem cells have the potential to play a valuable role in the development of regenerative medicine are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, those risks identified in AMAG’s filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2015, its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2016, June 30, 2016 and September 30, 2016 and subsequent filings with the SEC. Any such risks and uncertainties could materially and adversely affect AMAG’s results of operations, its profitability and its cash flows, which would, in turn, have a significant and adverse impact on AMAG’s stock price. AMAG cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. Cord Blood Registry® and CBR® are registered trademarks of CBR Systems, Inc.


Total GAAP quarterly revenue increased 50% to $143.8 million, driven by record sales of Makena® Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for the third quarter ended September 30, 2016. Total revenue for the third quarter of 2016 increased approximately 50% to $143.8 million. This increase was driven by record sales of Makena and the recognition of a full quarter of revenue from Cord Blood Registry® (CBR), which was acquired by AMAG on August 17, 2015. The company reported third quarter 2016 operating income of $38.8 million and net income of $16.2 million. Non-GAAP adjusted EBITDA for the third quarter of 2016 increased to $76.2 million1, or 44%, versus the same period in 2015. Non-GAAP net income for the third quarter of 2016 increased to $61.8 million1, or 46%, versus the same period in 2015. "We executed well against our key priorities in the third quarter, delivering strong financial results and hitting key milestones in our next-generation development programs," stated William Heiden, AMAG's chief executive officer. "Our Makena subcutaneous auto-injector program is on-track for an sNDA filing in the second quarter of next year and the Feraheme sNDA submission seeking approval of a broader label has been accelerated to mid-year 2017." "We have updated the company's financial guidance based on our fourth quarter expectations of continued strong top and bottom line performance, building on our successes achieved in the third quarter,” Mr. Heiden continued. Financial Results (GAAP Basis) Total revenues for the third quarter of 2016 were $143.8 million, compared with $96.2 million in the third quarter of 2015. This increase is related to record sales of Makena and the recognition of a full quarter of revenue from CBR, which was acquired by AMAG on August 17, 2015. Net product sales of Makena increased to $93.4 million in the third quarter of 2016, compared with $65.2 million in the same period last year. This 43% growth in Makena sales was primarily driven by the successful launch of the single-dose, preservative-free formulation and strong growth in the company’s Makena @Home program. Sales of Feraheme and MuGard® totaled $22.4 million in the third quarter of 2016, compared with $23.8 million in the third quarter of 2015. Service revenue from CBR totaled $28.0 million in the third quarter of 2016, as compared to $7.2 million in the third quarter of 2015. Total costs and expenses, including costs of product sales and services, totaled $105.0 million for the third quarter of 2016, compared with $97.5 million for the same period in 2015. The increase in operating expenses in 2016 was related to: (i) higher research and development expenses for the company's next generation development programs, (ii) higher selling, general and administrative expenses due to the recognition of a full quarter of CBR-related expenses, and (iii) higher non-cash amortization of the Makena intangible asset. These increases were partially offset by expenses in the third quarter of 2015 that did not recur in 2016 related to an upfront payment for AMAG's exclusive option to acquire rights to a development stage asset to treat severe preeclampsia (Velo) and CBR-related acquisition costs. Third quarter 2016 operating income totaled $38.8 million, compared with a $1.4 million loss in the third quarter of last year. The company reported net income of $16.2 million, or $0.47 per basic share and $0.43 per diluted share, for the third quarter of 2016, compared with a net loss of $20.6 million, or $0.62 per basic and diluted share, for the same period in 2015. Balance Sheet Highlights The company’s cash, cash equivalents and investments increased by $147.8 million in the first nine months of 2016 to approximately $614.1 million, net of $20.0 million utilized to repurchase the company’s common stock and $13.1 million to repay debt. Total debt (principal amount outstanding), including $200 million of convertible debt, was approximately $1.03 billion as of September 30, 2016. For the 12 months ended September 30, 2016, sales of Makena exceeded $300 million, triggering a $100 million milestone that will be paid to former Lumara Health shareholders in the fourth quarter of 2016. "In the third quarter, we once again generated strong cash flow as a result of our solid commercial execution and operating discipline,” stated Ted Myles, chief financial officer of AMAG. "We are now in an even better position to capitalize on acquisition or licensing opportunities that would diversify and expand our product portfolio." Financial Results (Non-GAAP Basis)1,2 Non-GAAP revenues totaled $145.8 million in the third quarter of 2016, up from $103.5 million in the third quarter of 2015. Non-GAAP CBR revenue totaled $29.9 million in the third quarter of 2016, compared with $14.5 million in the same period in 2015. CBR's financial results for the third quarter of 2015 include only a portion of the quarter, as AMAG purchased CBR on August 17, 2015. The difference between GAAP and non-GAAP revenue for the quarter represents purchase accounting adjustments related to CBR deferred revenue. Total non-GAAP costs and expenses, including costs of product sales and services, totaled $69.6 million in the third quarter of 2016, compared with total non-GAAP costs and expenses of $50.6 million in the same period in 2015. Non-GAAP adjusted EBITDA for the third quarter of 2016 was $76.2 million, compared with $52.8 million for the same period in 2015. The company generated third quarter 2016 non-GAAP net income of $61.8 million, or $1.81 per non-GAAP basic share and $1.78 per non-GAAP diluted share. In the third quarter of 2015, non-GAAP net income totaled $42.3 million, or $1.27 per non-GAAP basic share and $1.02 per non-GAAP diluted share. Non-GAAP diluted shares for the third quarter of 2016 do not include 7.4 million of potentially dilutive shares from the convertible notes, as the stock price was below the convertible notes' exercise price. Conference Call and Webcast Access AMAG Pharmaceuticals, Inc. will host a conference call and webcast with slides today at 8:00 a.m. ET, during which management will discuss the company’s financial and operating results and recent developments. To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on November 3, 2016 through midnight on November 10, 2016. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 96588865. The call will be webcast with slides and accessible through the Investors section of the company’s website at www.amagpharma.com. The webcast replay will be available from approximately 11:00 a.m. ET on November 3, 2016 through midnight on December 3, 2016. Use of Non-GAAP Financial Measures AMAG has presented certain non-GAAP financial measures, including non-GAAP revenues, non-GAAP costs and expenses, non-GAAP adjusted EBITDA (earnings before income taxes, depreciation and amortization), non-GAAP net income and non-GAAP basic and diluted net income per share. These non-GAAP financial measures exclude certain amounts, revenue, expenses, income or dilutive shares from the corresponding financial measures determined in accordance with accounting principles generally accepted in the U.S. (GAAP). Management believes this non-GAAP information is useful for investors, taken in conjunction with AMAG’s GAAP financial statements, because it provides greater transparency regarding AMAG’s operating performance and prospects for future performance and allows investors to better compare performance over different periods. Management uses these measures, among other factors, to assess and analyze operational results and trends and to make financial and operational decisions, including in compensation decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of AMAG’s operating results as reported under GAAP, not as a substitute for GAAP financial measures, and AMAG encourages investors to review its consolidated financial statements and publicly filed reports in their entirety. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Due to the adjustments made to GAAP net income (loss) and GAAP net income (loss) per share to calculate non-GAAP net income and non-GAAP net income per share, the non-GAAP measures are higher than GAAP net income (loss) and GAAP net income (loss) per share. Non-GAAP net income and non-GAAP net income per share should not be considered measures of our liquidity. The determination of the amounts that are excluded from non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts. Reconciliations between these non-GAAP financial measures and the most comparable GAAP financial measures are included in the tables accompanying this press release after the unaudited condensed consolidated financial statements. About AMAG AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com. About Makena® (hydroxyprogesterone caproate injection) Makena® is a progestin indicated to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth.                 The effectiveness of Makena is based on improvement in the proportion of women who delivered <37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of Makena has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth. Makena should not be used in women with any of the following conditions: blood clots or other blood clotting problems, breast cancer or other hormone-sensitive cancers, or history of these conditions; unusual vaginal bleeding not related to the current pregnancy, yellowing of the skin due to liver problems during pregnancy, liver problems, including liver tumors, or uncontrolled high blood pressure. Before patients receive Makena, they should tell their healthcare provider if they have an allergy to hydroxyprogesterone caproate, castor oil, or any of the other ingredients in Makena; diabetes or prediabetes, epilepsy, migraine headaches, asthma, heart problems, kidney problems, depression, or high blood pressure. In one clinical study, certain complications or events associated with pregnancy occurred more often in women who received Makena. These included miscarriage (pregnancy loss before 20 weeks of pregnancy), stillbirth (fetal death occurring during or after the 20th week of pregnancy), hospital admission for preterm labor, preeclampsia (high blood pressure and too much protein in the urine), gestational hypertension (high blood pressure caused by pregnancy), gestational diabetes, and oligohydramnios (low amniotic fluid levels). Makena may cause serious side effects including blood clots, allergic reactions, depression, and yellowing of the skin and the whites of the eyes. The most common side effects of Makena include injection site reactions (pain, swelling, itching, bruising, or a hard bump), hives, itching, nausea, and diarrhea. About Feraheme® (ferumoxytol) Feraheme received marketing approval from the FDA on June 30, 2009 for the treatment of IDA in adult CKD patients and was commercially launched by AMAG in the U.S. shortly thereafter. Ferumoxytol is protected in the U.S. by six issued patents covering the composition and dosage form of the product. Each issued patent is listed in the FDA’s Orange Book, the last of which expires in June 2023. Fatal and serious hypersensitivity reactions including anaphylaxis have occurred in patients receiving Feraheme. Initial symptoms may include hypotension, syncope, unresponsiveness, cardiac/cardiorespiratory arrest. Feraheme is contraindicated in patients with a known hypersensitivity to Feraheme or any of its components, or a history of allergic reaction to any intravenous iron product. For additional product information, please see full Prescribing Information, including Boxed Warning, available at www.feraheme.com. About Cord Blood Registry® (CBR) CBR is the world’s largest private newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing more than 600,000 umbilical cord blood and cord tissue units. CBR is dedicated to advancing the clinical application of newborn stem cells by partnering with reputable research institutions on FDA-regulated clinical trials for conditions that have no cure today. For more information, visit www.cordblood.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, expectations for AMAG’s next generation development programs for Makena, including the anticipated timing to file an sNDA; expectations for AMAG’s Phase 3 clinical trial for the broader indication for Feraheme, including the anticipated timing of an sNDA submission; AMAG’s 2016 updated financial guidance, including GAAP and non-GAAP revenues, GAAP operating income, non-GAAP adjusted EBITDA and GAAP and non-GAAP net income; AMAG's intention to pay a $100 million milestone to former Lumara Health shareholders in the fourth quarter of 2016; AMAG’s belief that the generation of strong cash flows in the first nine months of 2016 puts AMAG in a better position to diversify and expand its portfolio; and beliefs that newborn stem cells have the potential to play a valuable role in the development of regenerative medicine are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, those risks identified in AMAG’s filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2015, its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2016 and June 30, 2016 and subsequent filings with the SEC. Any such risks and uncertainties could materially and adversely affect AMAG’s results of operations, its profitability and its cash flows, which would, in turn, have a significant and adverse impact on AMAG’s stock price. AMAG cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. AMAG Pharmaceuticals® and Feraheme® are registered trademark of AMAG Pharmaceuticals, Inc. MuGard® is a registered trademark of Abeona Therapeutics, Inc. Makena® is a registered trademark of AMAG Pharmaceuticals IP, Ltd.  Cord Blood Registry® and CBR® are registered trademarks of CBR Systems, Inc.


Yang E.K.L.,Cord Blood Registry | Yang E.K.L.,Tzu Chi University | Hung J.H.,University of Ottawa | Lin P.Y.,Cord Blood Registry
Tissue Antigens | Year: 2015

Two nucleotide changes at residue 142 (G → A) and residue 144 (A → C) of HLA-A*02:01:01:01 result in a novel allele, HLA-A*02:570. © 2015 John Wiley & Sons A/S.


Yang K.-L.,Cord Blood Registry | Yang K.-L.,Tzu Chi University | Lin P.-Y.,Cord Blood Registry
Tzu Chi Medical Journal | Year: 2013

Objective: HLA-A*11:127N and HLA-B*40:221 are two rarely observed alleles in the HLA-A locus and in HLA-B locus, respectively. The objective of this study is to report the two plausible deduced HLA haplotypes in association with HLA-A*11:127N and HLA-B*40:221 in unrelated Taiwanese bone marrow stem cell donors. Materials and Methods: A sequence-based typing method was used to confirm the low incidence alleles observed. Polymerase chain reaction was carried out to amplify exons 2, 3, and 4 of the HLA-A, -B, and-Cloci with group-specific primer sets. Amplicons were sequenced using the BigDye Terminator Cycle Sequencing Ready Reaction Kit in both directions according to the manufacturer's protocol. Results: We deduced the two probable HLA haplotypes in association with A*11:127N and B*40:221 as HLA-A*11:127N-B*54:01-DRB1*04:05 and HLA-A*11:01-B*40:221-C*03:04-DRB1*14:54-DQB1*05:02, respectively. Conclusion: Information on the two deduced HLA haplotypes associated with the rare A*11:127N and B*40:221 alleles that we report here is valuable for HLA tissue typing laboratories for reference purposes and for stem cell transplantation donor search coordinators to determine the likelihood of finding compatible donors in unrelated bone marrow donor registries for patients bearing these two uncommon HLA alleles. Because A*11:127N and B*40:221 have so far been found only in the Taiwanese population, we think the haplotypes that we report here are most likely conserved in Taiwanese. © 2013.


The invention provides a combination of an insurance policy and a savings plan in which a periodic deposit is made. The insurance policy stipulates that a depositor is indemnified for expenses incurred for a medical or cosmetic treatment requiring body material of the type deposited by a depositor in depository. The savings plan specifies that an accrued value of the savings plan may be utilized to defer costs of maintaining the body tissue or body organ in the depository if the depositor ceases to pay a predetermined periodic service payment to the depository. The invention also provides a system for a method for providing the combination of the invention, and a system for carrying out the method of the invention.


Market Research Report on Cord Blood market 2016 is a professional and in-depth study on the current state of the Cord Blood worldwide. First of all,"Global Cord Blood Market 2016" report provides a basic overview of the Cord Blood industry including definitions, classifications, applications and Cord Blood industry chain structure. The analysis is provided for the Cord Blood international market including development history, Cord Blood industry competitive landscape analysis.  This report "Worldwide Cord Blood Market 2016" also states import/export, supply and consumption figures and Cord Blood market cost, price, revenue and Cord Blood market's gross margin by regions (United States, EU, China and Japan), as well as other regions can be added in Cord Blood Market area. Major Manufacturers are covered in this research report are Cord Blood Registry FamilyCord CorCell AssureImmune Elie Katz Umbilical New England Cord Blood Bank Cord Blood Solutions CordTrack Cord:Use NeoStem This report studies Cord Blood in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with sales, price, revenue and market share. Then, the report focuses on worldwide Cord Blood market key players with information such as company profiles with product picture as well as specification. Related information to Cord Blood market- capacity, production, price, cost, revenue and contact information. Aslo includes Cord Blood industry's - Upstream raw materials, equipment and downstream consumers analysis is also carried out. What’s more, the Cord Blood market development trends and Cord Blood industry marketing channels are analyzed. Finally, "Worldwide Cord Blood Market" Analysis- feasibility of new investment projects is assessed, and overall research conclusions are offered.


Loading Cord Blood Registry collaborators
Loading Cord Blood Registry collaborators